Edition:
India

Julie Steenhuysen

Abbott hits record high as diabetes device fuels profit beat

17 Jul 2019

Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.

Abbott to hike production of lower-cost glucose monitors as diabetes soars

16 Jul 2019

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

26 Jun 2019

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

02 Jun 2019

CHICAGO AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.

CORRECTED-Lynparza stalls pancreatic cancer in patients with BRCA mutations -study

02 Jun 2019

CHICAGO, June 2 AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go longer without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.

Merck's Keytruda sets new five-year survival standard for advanced lung cancer

01 Jun 2019

CHICAGO Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting on Saturday.

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

11 May 2019

INDIANAPOLIS Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

11 May 2019

INDIANAPOLIS, May 10 Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of first-time patients at 37.7 percent, for the first time outstripping Amgen’s Aimovig, whose share dropped to 37.2 percent as of April 26. Teva came in at a 25.1 percent share, according to an analyst who reviewed the data.

World News